Male Infertility Market

Male Infertility Market by Treatment (Surgery, {Varicocelectomy, Varicocele Embolization, Transurethral Ejaculatory Duct Resection, Others} and Medication), Testing (DNA Fragmentation, Sperm Agglutination,  Oxidative Stress, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of male infertility due to lifestyle disorders, increased awareness and social acceptance for treatment options, and increase in technological advancement across the globe.

The male infertility market was valued at USD 3,845.55 million in 2024, growing at a CAGR of 3.42% during the forecast period from 2025 to 2032, to reach USD 5,007.15 million by 2032. The increasing prevalence of male infertility, driven by lifestyle disorders, structural abnormalities, genetic factors, and other underlying causes, is significantly fueling the global market for male infertility treatments. Additionally, rising awareness and growing social acceptance have helped reduce stigma, encouraging more men to seek medical intervention. Advancements in diagnostic technologies, such as genetic testing and advanced imaging, along with innovative treatments like hormonal therapies and minimally invasive surgical procedures, are improving both treatment efficacy and accessibility. These factors are expected to drive strong demand for male infertility solutions, fostering market growth across both developed and developing regions from 2025 to 2032.

Male Infertility Market Dynamics:

According to the Global Burden of Disease study, the total number of male infertility cases worldwide reached 55 million in 2021, with a prevalence rate of 1,354.8 per 100,000 population. Additionally, data from the European Union (2021) reported that over 25 million EU citizens faced fertility issues, with male factor infertility contributing to approximately 40% of all infertile couples.  

Male infertility is commonly caused by difficulties in semen ejection, low or absent sperm levels, and abnormalities in sperm morphology and motility. The increasing prevalence of male infertility highlights a complex interplay of environmental, lifestyle, and demographic factors that negatively impact reproductive health, driving demand for infertility treatments.  

Lifestyle factors such as poor diet, lack of physical activity, obesity, excessive alcohol consumption, smoking, and chronic stress are major contributors to declining male fertility. These factors can lead to hormonal imbalances, reduced sperm quality, and lower sperm count. Additionally, exposure to environmental toxins and prolonged heat, such as frequent laptop use on laps, exacerbates the issue. Addressing these factors through healthier living habits is essential for improving male fertility and overall reproductive health.  

Obesity, in particular, is a significant risk factor for male infertility. According to World Health Organization data from 2022, approximately 390 million children and adolescents (aged 5–19 years) were overweight worldwide, with 21% of boys in this age group classified as overweight. Obesity can lead to reproductive health issues, including low sperm count, poor sperm quality, and erectile dysfunction. As obesity rates continue to rise, the demand for male infertility treatments is also expected to grow, further fueling market expansion.  

Additionally, the expansion of reproductive health services is enhancing access to infertility treatments. For instance, in November 2022, Sidra Medicine launched a new male infertility clinic in Qatar as part of its expansion of private reproductive health services.  

Overall, these factors are expected to drive significant growth in the male infertility treatment market during the forecast period.

However, the high cost of treatment associated with male infertility treatments and the side effects and risks associated with male infertility treatment procedures may hinder the future market of male infertility.

Male Infertility Market Segment Analysis:

Male Infertility Market by Treatment (Surgery, {Varicocelectomy, Varicocele Embolization, Transurethral Ejaculatory Duct Resection, Others} and Medication), Testing (DNA Fragmentation, Sperm Agglutination, Oxidative Stress, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the testing segment of the male infertility market, DNA fragmentation assessment is expected to hold the highest revenue share in 2024. This diagnostic tool has gained significant traction in male infertility evaluation, positively influencing market dynamics. Unlike traditional semen analysis, DNA fragmentation testing provides deeper insights into sperm quality, detecting DNA damage that may impair fertility even when conventional parameters such as sperm count and motility appear normal. This enhances diagnostic accuracy, enabling clinicians to better understand the underlying causes of male infertility.  

DNA fragmentation assessment is particularly crucial for couples undergoing assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). High levels of sperm DNA fragmentation have been linked to lower ART success rates and increased miscarriage risk. By identifying and addressing DNA damage before ART, clinicians can improve embryo quality and enhance the chances of a successful pregnancy.  

Additionally, strategic initiatives such as new product launches and regulatory approvals by key industry players are further propelling market growth. For instance, in March 2021, Legace introduced a user-friendly sperm DNA fragmentation (SDF) analysis for at-home testing, capitalizing on the growing consumer demand for accessible fertility diagnostics. Such innovations are expected to accelerate market adoption and drive growth in this crucial segment.  

Considering these factors, the DNA fragmentation testing category is poised to generate substantial revenue, significantly contributing to the overall expansion of the global male infertility market during the forecast period.

North America is expected to dominate the overall male infertility market:

Among all regions, North America is expected to hold the largest share of the male infertility market in 2024. This dominance is driven by multiple factors, including a high prevalence of lifestyle-related disorders such as obesity, stress, and substance abuse, which contribute significantly to male infertility. The region’s advanced healthcare infrastructure and widespread access to cutting-edge diagnostic and treatment technologies such as assisted reproductive technologies (ART), genetic testing, and hormonal therapies further support market growth. Additionally, increasing awareness and social acceptance of male infertility treatments, along with favorable reimbursement policies and substantial investments in research and development, have created a robust market environment. The presence of key industry players and a strong focus on innovation further solidify North America's leadership in this sector.  

According to the National Institute of Child Health and Human Development (2024), approximately 9% of men in the United States have experienced infertility. Furthermore, data from the American Society for Reproductive Medicine (2023) indicate a 22% increased risk of infertility among individuals who smoke or use tobacco in the U.S. Factors such as poor diet, sedentary behavior, chronic stress, environmental exposures, genetic predispositions, and structural abnormalities are contributing to the rising prevalence of male infertility. This increasing incidence has driven demand for advanced diagnostic tools, including genetic testing, imaging, and hormonal assessments, as well as innovative treatment options such as ART, sperm retrieval procedures, and hormonal therapies.  

Moreover, smoking remains a major risk factor for male infertility. According to the Centers for Disease Control and Prevention (CDC, 2024), approximately 13.1% of adult men in the United States smoked cigarettes in 2021. Cigarette smoke contains over 7,000 harmful chemicals that damage sperm quality, reduce sperm count, and impair function, leading to decreased motility, DNA fragmentation, and abnormal morphology. Smoking is also linked to erectile dysfunction and lower testosterone levels, further contributing to fertility issues. As a result, men who smoke are more likely to require ART solutions such as IVF and ICSI, thereby boosting demand for infertility treatments.  

Additionally, key market players are actively driving advancements in male infertility treatment. For instance, in May 2021, Posterity Health launched a comprehensive digital platform for male fertility management in the U.S., enhancing assessment, evaluation, and treatment capabilities. Such initiatives are expected to further strengthen market growth in North America.  

Considering these factors, North America is poised to experience significant market expansion in male infertility treatment, with continued growth projected from 2025 to 2032.

Male Infertility Market Key Players:

Some of the key market players operating in the male infertility market include Merck KGaA, Halotech DNA, Caerus Biotech, Vitrolife, CinnaGen Co., Andrology Solutions, Aytu BioScience, Inc., Bayer Healthcare, SCSA Diagnostics, Inc., Cordex Pharma, Inc., ASKA Pharmaceutical Co. Ltd., Novo Nordisk A/S,  Fertility Solutions Inc., NUH Life, Give Legacy, Inc., and others.

Recent Developmental Activities in the Male Infertility Market:

• In June 2024, Ferring Pharmaceuticals, in partnership with Posterity Health, launched a new Male Fertility program on Ferring’s Fertility Out Loud platform, empowering men to take the initiative in understanding their fertility status.
• In September 2023, Merck KGaA launched a fertility benefits program for male employees in eight markets in Europe, Asia, and Latin America.

Key Takeaways From the Male Infertility Market Report Study:

• Market size analysis for current male infertility size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the male infertility market.
• Various opportunities available for the other competitors in the male infertility market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current male infertility market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for male infertility market growth in the coming future?

Target Audience Who Can be Benefited From This Male Infertility Market Report Study:

• Male infertility product providers
• Research organizations and consulting companies 
• Male Infertility -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in male infertility 
• Various end-users who want to know more about the male infertility market and the latest technological developments in the male infertility market.  

Frequently Asked Questions for the Male Infertility Market:

1. What is male infertility?

• Male infertility refers to a condition where a man has a reduced ability to cause pregnancy in a female partner, despite regular, unprotected intercourse. This can include low sperm count, poor sperm motility, abnormal sperm shape, hormonal imbalances, or physical blockages.

2. What is the market for male infertility?

• The male infertility market was valued at USD 3,845.55 million in 2024, growing at a CAGR of 3.42% during the forecast period from 2025 to 2032, to reach USD 5,007.15 million by 2032. 

3. What are the drivers for the male infertility market?

• The rising prevalence of male infertility, driven by lifestyle disorders, structural or anatomical issues, genetic factors, and other underlying causes, is significantly propelling the global market for male infertility treatments. Increased awareness and social acceptance of treatment options have reduced stigma, encouraging more men to seek medical help. Advancements in diagnostic technologies, such as genetic testing and imaging, alongside innovative treatments like hormonal therapies, assisted reproductive technologies (ART), and minimally invasive surgical procedures, are enhancing treatment efficacy and accessibility. Collectively, these factors are expected to create a robust demand for male infertility solutions, driving market growth across developed and developing regions during the forecast period from 2025 to 2032.

4. Who are the key players operating in the male infertility market?

• Some of the key market players operating in the male infertility market include Merck KGaA, Halotech DNA, Caerus Biotech, Vitrolife, CinnaGen Co., Andrology Solutions, Aytu BioScience, Inc., Bayer Healthcare, SCSA Diagnostics, Inc., Cordex Pharma, Inc., ASKA Pharmaceutical Co. Ltd., Novo Nordisk A/S,  Fertility Solutions Inc., NUH Life, Give Legacy, Inc., and others.

5. Which region has the highest share in the male infertility market?

• Among all the regions, North America is expected to hold the largest share of the male infertility market in 2024. North America is expected to dominate the male infertility market due to several factors, including the region's high prevalence of lifestyle-related disorders such as obesity, stress, and substance abuse, which contribute to infertility. Advanced healthcare infrastructure and widespread access to cutting-edge diagnostic and treatment technologies, such as assisted reproductive technologies (ART), genetic testing, and hormonal therapies, further support market growth. Additionally, increasing awareness and social acceptance of male infertility treatments, along with favorable reimbursement policies and significant investments in research and development, have fostered a robust market environment. The presence of key market players and a growing focus on innovation also solidify North America's leadership in this sector.